Pain Matters Podcast Network · AAPM - American Academy of Pain Medicine

Special Episode: What FTC's Landmark Decision to Ban Noncompetes Means in Medicine

·41 min·2 clips

Michael Johnson says employed physicians are the main beneficiaries, while private equity groups may be the most harmed.

The episode opens on the FTC's April 23rd ruling to ban non-competes and treats it as a practical question for medicine, with pain medicine as a focused test case. That frame holds up. Michael Johnson walks through how employers may respond if noncompetes weaken, including the likely move toward beefed-up non-solicit clauses that carry some of the same pressure. Nothing disappears cleanly. He also notes that a non-solicit can, in some circumstances, become so punitive that someone might argue it is functionally a non-compete. That point needs care. The conversation then widens to the other ways employers can make leaving difficult, which means the legal risk does not end with one clause. The contract table has more than one lever. The hosts move into the FTC's own limits, including the fact that its budget is set by Congress and that limited resources can leave gray areas and less clear enforcement. Gray areas are bad governance. A long exchange follows on policy literacy, using the speaker's public health training to show how often clinicians are asked to navigate agency authority without much formal training. The policy side matters here. The episode then lays out the stakeholder map, with employed physicians positioned as the group most likely to gain movement if the ban survives legal challenges. They are the clearest beneficiaries. Private equity groups are framed as the likely biggest losers, because their model often depends on acquisition, consolidation, and limiting physician mobility through contracts. That is the business model tension. Hospitals, patients, and other employers remain part of the picture, but the practical focus keeps returning to what happens when a physician tries to leave. Departure is the stress test. By the end, the discussion makes clear that even if noncompetes fall, tougher non-solicits and other restrictions may still shape the next round of negotiations. The issue is broader than a single ban.

As heard by us

A clear look at how the FTC's noncompete ruling could reshape physician contracts and departure terms.

The episode centers on the FTC's April 23 ruling to ban noncompetes and uses pain medicine as the lens for explaining what may follow. It is strongest when it draws a clean line between the agency's authority and Congress's leverage over the FTC's resources, then connects that…

Read the full review in PlayNext →

Why you'd press play

If noncompetes are on your radar, this episode breaks down the pressure points in pain medicine contracts.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Pain Matters Podcast Network